Response by Elliott et al to Letter Regarding Article, "Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy"

被引：1
|
作者：
Elliott, Perry [1 ]
Gundapaneni, Balarama [2 ]
Sultan, Marla B. [3 ]
机构：
[1] UCL, London, England
[2] Pfizer Inc, Groton, CT 06340 USA
[3] Pfizer Inc, New York, NY USA
来源：
CIRCULATION-HEART FAILURE | 2022年 / 15卷 / 07期
关键词：
D O I：
10.1161/CIRCHEARTFAILURE.122.009637
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Letter by Baldovino et al Regarding Article, "Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy"
    Baldovino, Simone
    Costanzo, Piera
    Roccatello, Dario
    CIRCULATION-HEART FAILURE, 2022, 15 (07)
  • [2] Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
    Elliott, Perry
    Drachman, Brian M.
    Gottlieb, Stephen S.
    Hoffman, James E.
    Hummel, Scott L.
    Lenihan, Daniel J.
    Ebede, Ben
    Gundapaneni, Balarama
    Li, Benjamin
    Sultan, Marla B.
    Shah, Sanjiv J.
    CIRCULATION-HEART FAILURE, 2022, 15 (01) : E008193
  • [3] Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy
    Damy, T.
    Elliott, P.
    Gundapaneni, B.
    Tai, S. See
    Sultan, M. B.
    Drachman, B. M.
    EUROPEAN HEART JOURNAL, 2020, 41 : 2142 - 2142
  • [4] Response by Kazi et al to Letter Regarding Article, "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy"
    Kazi, Dhruv S.
    Bellows, Brandon K.
    Spertus, John A.
    Baron, Suzanne J.
    Shen, Changyu
    Cohen, David J.
    Yeh, Robert W.
    Arnold, Suzanne V.
    Sperry, Brett W.
    Maurer, Mathew S.
    Shah, Sanjiv J.
    CIRCULATION, 2020, 142 (15) : E212 - E213
  • [5] Long-term Survival Benefit of Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy
    Patel, Jignesh
    Elliott, Perry
    Gundapaneni, Balarama
    Li, Benjamin
    Sultan, Marla
    Grogan, Martha
    JOURNAL OF CARDIAC FAILURE, 2020, 26 (10) : S64 - S65
  • [6] Letter by Rozenbaum et al Regarding Article, "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy"
    Rozenbaum, Mark H.
    Kemner, Jason
    Parasuraman, Bhash
    CIRCULATION, 2020, 142 (15) : E210 - E211
  • [7] Effects of tafamidis on heart failure hospitalization: the tale of the dog that did not bark. Letter regarding the article 'Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms'
    Aimo, Alberto
    Vergaro, Giuseppe
    Emdin, Michele
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 (02) : 526 - 526
  • [8] Improved long-term survival with tafamidis treatment in patients with transthyretin amyloid cardiomyopathy and severe heart failure symptoms
    Elliott, Perry
    Gundapaneni, Balarama
    Sultan, Marla B.
    Ines, Monica
    Garcia-Pavia, Pablo
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (11) : 2060 - 2064
  • [9] Letter regarding the article 'Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study'
    Dobner, Stephan
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 (04) : 681 - 682
  • [10] Reply to the letter regarding the article 'Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study'
    Damy, Thibaud
    Sultan, Marla B.
    Witteles, Ronald
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 (06) : 1057 - 1058
12345